ArticleCase reports in dermatology
Dupilumab's Successful Journey in Pityriasis Lichenoides Chronica Followed by the Intriguing Reemergence of Vitiligo after Monobenzone Depigmentation: A Case Report.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric Pityriasis Lichenoides Chronica, A Rare Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pityriasis lichenoides (PL) is an inflammatory skin disorder encompassing both acute (PLEVA) and chronic (PLC) subtypes, which share overlapping clinical and histopathological features. Standard treatment modalities include oral antibiotics, phototherapy, and immunosuppressive agents. Dupilumab, an IL-4Rα antagonist approved for atopic dermatitis, has been used off-label for various inflammatory skin conditions. However, its role in PLC management remains poorly documented. Case Presentation: We report a case of PLC successfully treated with dupilumab. The patient had a history of vitiligo and had previously undergone monobenzone depigmentation therapy. Due to concerns regarding potential pigmentary changes, dupilumab was initiated with a loading dose of 600 mg, followed by 300 mg biweekly. After 3 months of therapy, there was significant improvement in PLC lesions and pruritus, with only residual erythematous plaques. Unexpectedly, spontaneous skin repigmentation occurred, contrasting with previous reports of vitiligo exacerbation following dupilumab use. The patient resumed monobenzone therapy without experiencing PLC recurrence or worsening pruritus. Conclusion: This case highlights dupilumab's potential as an effective treatment for PLC and its possible role in promoting skin repigmentation in a patient with prior vitiligo. These findings suggest a potential link between type 2 inflammation and PLC pathogenesis, warranting further investigation. Dupilumab may represent a promising therapeutic alternative for refractory PLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.